Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the fourteen ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $187.71.

A number of brokerages have recently issued reports on JAZZ. Royal Bank of Canada lowered their price target on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating on the stock in a report on Wednesday, February 26th. Truist Financial upped their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th. JPMorgan Chase & Co. upped their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. UBS Group upgraded shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their price target for the company from $145.00 to $179.00 in a research report on Friday, March 7th. Finally, Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $130.00 to $170.00 in a research report on Thursday, February 13th.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock traded down $1.81 on Wednesday, reaching $138.76. The stock had a trading volume of 3,643,788 shares, compared to its average volume of 703,902. Jazz Pharmaceuticals has a 1 year low of $99.06 and a 1 year high of $148.06. The company has a market cap of $8.43 billion, a P/E ratio of 19.54, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The business's 50 day moving average is $131.41 and its two-hundred day moving average is $121.61.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,800 shares of the company's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.87, for a total value of $550,506.00. Following the sale, the executive vice president now owns 33,318 shares in the company, valued at approximately $4,826,778.66. This represents a 10.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the company's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $122.31, for a total transaction of $183,465.00. Following the completion of the sale, the chief executive officer now owns 439,744 shares in the company, valued at approximately $53,785,088.64. This trade represents a 0.34 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 28,736 shares of company stock valued at $4,022,825 over the last quarter. 4.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. CIBC Asset Management Inc bought a new position in shares of Jazz Pharmaceuticals in the third quarter worth approximately $209,000. Natixis Advisors LLC lifted its stake in shares of Jazz Pharmaceuticals by 7.6% in the third quarter. Natixis Advisors LLC now owns 22,834 shares of the specialty pharmaceutical company's stock worth $2,544,000 after buying an additional 1,603 shares in the last quarter. Swiss National Bank lifted its stake in shares of Jazz Pharmaceuticals by 0.3% in the third quarter. Swiss National Bank now owns 117,000 shares of the specialty pharmaceutical company's stock worth $13,035,000 after buying an additional 400 shares in the last quarter. Advisors Asset Management Inc. lifted its stake in shares of Jazz Pharmaceuticals by 3.9% in the third quarter. Advisors Asset Management Inc. now owns 9,624 shares of the specialty pharmaceutical company's stock worth $1,072,000 after buying an additional 364 shares in the last quarter. Finally, Foundry Partners LLC lifted its stake in shares of Jazz Pharmaceuticals by 10.9% in the third quarter. Foundry Partners LLC now owns 3,362 shares of the specialty pharmaceutical company's stock worth $375,000 after buying an additional 331 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.